PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
Philip SuteraJongmyung KimRitesh KumarRebecca A DeekRyan StephensonTina MayerBiren SaraiyaSaum GhodoussipourThomas JangDavid GolombosVignesh PackiamRonald EnnisLara HathoutSalma K JabbourOzan GulerCem OnalPhuoc T TranMatthew P DeekPublished in: The Prostate (2024)
PIK3/Akt/mTOR pathway alterations were common in mCSPC and associated with poorer prognosis. The genetic landscape of PIK3/Akt/mTOR pathway altered tumors differed from wildtype tumors. Additional studies are needed to better understand and target the PIK3/Akt/mTOR pathway in mCSPC.